BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Llavero NT, Gimeno-valiente F, Gambardella V, Huerta M, Keranen SR, Bruixola G, Fontana E, Ciarpaglini CM, Zuñiga S, Rentero P, Fleitas T, Papaccio F, Moro D, Pla V, Nyamundanda G, Castillo J, Sadanadam A, Espí A, Roda D, Cervantes A. Mutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype. Annals of Oncology 2019;30:v198. [DOI: 10.1093/annonc/mdz246] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Cherri S, Libertini M, Zaniboni A. New drugs for the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2021; 13(11): 1551-1560 [PMID: 34853636 DOI: 10.4251/wjgo.v13.i11.1551] [Reference Citation Analysis]
2 Parent P, Cohen R, Rassy E, Svrcek M, Taieb J, André T, Turpin A. A comprehensive overview of promising biomarkers in stage II colorectal cancer. Cancer Treatment Reviews 2020;88:102059. [DOI: 10.1016/j.ctrv.2020.102059] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]